Technology ID
TAB-3616

Mmut P.R106C/P.R106C Knock-In Methylmalonyl-CoA Mutase (Mmut) Allele mouse models for the Study of Methylmalonic Acidemia (MMA)

E-Numbers
E-159-2020-0
Lead Inventor
Venditti, Charles (National Human Genome Research Institute (NIH/NHGRI))
Co-Inventors
Schneller, Jessica (National Human Genome Research Institute (NIH/NHGRI))
Chandler, Randy (National Human Genome Research Institute (NIH/NHGRI))
Applications
Therapeutics
Research Materials
Therapeutic Areas
Ophthalmology
Oncology
Infectious Disease
Endocrinology
Dental
Cardiology
Lead IC
NHGRI
Isolated Methylmalonic Acidemia (MMA) comprises a relatively common and heterogeneous group of inborn errors of metabolism. In order to create mouse models of MMA to resemble the pathogenic mutations seen in patients, the NHGRI scientist used genome editing to generate new mutants of the Mmut allele - p.R106C. This allele recapitulates a missense mutation seen in multiple patients with the disorder. Of note and emphasis is the fact that there are no transgene cassettes or other alternations to the Mmut locus in these new mouse models. These mice display elevations of MMA biomarkers, such as 2-methylcitrate, are viable, without obvious gross pathology, and fully fertile, they can be easily bred. These new models can be used for physiology studies, biomarker discovery, and to test the effects of gene therapy, cell therapy, mRNA therapy, nucleic acid therapies, small molecules, the microbiome, and especially genome editing using AAV, Cas/CRISPR, and other editing approaches as treatments for MMA and related conditions.
Commercial Applications
These new models can be used for physiology studies, biomarker discovery, and to test the effects of gene therapy, cell therapy, mRNA therapy, nucleic acid therapies, small molecules, the microbiome, and especially genome editing using adeno-associated viruses (AAV), Cas/CRISPR, and other editing approaches as treatments for MMA and related conditions.

Competitive Advantages
The mouse models are especially unique in that they more closely mimic the nature of mutations seen in patients and they can be bred in larger quantities than other mouse models and genotyped using digital droplet PCR. They also have MMA related disease processes in all the tissues and cells of the body. Furthermore, we have demonstrated the utility of these mice to test AAV gene therapy as a therapeutic intervention.
Licensing Contact:
Campbell, Eggerton
eggerton.campbell@nih.gov